Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - BMJ open, 2016 - bmjopen.bmj.com
Objective The present study investigated the effects of switching to different products of the
same off-patent active substance (brand name or generic) on therapy discontinuation or …

Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a'real …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - BMJ OPEN, 2016 - air.unimi.it
OBJECTIVE: The present study investigated the effects of switching to different products of
the same off-patent active substance (brand name or generic) on therapy discontinuation or …

Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a'real …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - BMJ Open, 2016 - europepmc.org
Objective The present study investigated the effects of switching to different products of the
same off-patent active substance (brand name or generic) on therapy discontinuation or …

[PDF][PDF] Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ' …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - core.ac.uk
Objective: The present study investigated the effects of switching to different products of the
same offpatent active substance (brand name or generic) on therapy discontinuation or …

Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a'real …

L Degli Esposti, D Sangiorgi, S Buda… - BMJ …, 2016 - pubmed.ncbi.nlm.nih.gov
Objective The present study investigated the effects of switching to different products of the
same off-patent active substance (brand name or generic) on therapy discontinuation or …

Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real …

L Degli Esposti, D Sangiorgi, S Buda… - BMJ …, 2016 - search.proquest.com
Objective The present study investigated the effects of switching to different products of the
same off-patent active substance (brand name or generic) on therapy discontinuation or …

[PDF][PDF] Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ' …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - academia.edu
Objective: The present study investigated the effects of switching to different products of the
same offpatent active substance (brand name or generic) on therapy discontinuation or …

[HTML][HTML] Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ' …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - BMJ Open, 2016 - ncbi.nlm.nih.gov
Objective The present study investigated the effects of switching to different products of the
same off-patent active substance (brand name or generic) on therapy discontinuation or …

[PDF][PDF] Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ' …

L Degli Esposti, D Sangiorgi, S Buda, E Degli Esposti… - air.unimi.it
Objective: The present study investigated the effects of switching to different products of the
same offpatent active substance (brand name or generic) on therapy discontinuation or …